Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

The Promise of CAR T-Cell Therapy for the Treatment of Cancer Stem Cells: A Short Review

Author(s): Naresh Poondla, Mohsen Sheykhhasan*, Mohammad Akbari, Pouria Samadi, Naser Kalhor and Hamed Manoochehri

Volume 17, Issue 5, 2022

Published on: 14 April, 2022

Page: [400 - 406] Pages: 7

DOI: 10.2174/1574888X17666220217101817

Price: $65

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a type of sophisticated tailored immunotherapy used to treat a variety of tumors. Immunotherapy works by utilizing the body's own immune system to discover and destroy malignant cells. In CAR-T therapy, a patient’s own immune cells are genetically engineered to recognize and attack cancer. Treatments employing CAR T-cells are currently showing promising therapeutic results in patients with hematologic malignancies, and their safety and feasibility in solid tumors have been verified. In this review, we will discuss in detail the likelihood that CAR Tcells inhibit cancer stem cells (CSCs) by selectively targeting their cell surface markers will ultimately improve the therapeutic response for patients with various forms of cancer. This review addresses the major components of cancer stem cell (CSC)-targeted CAR T-cells against malignancies, from bench to bedside.

Keywords: CAR T-cell, cancer stem cells, malignancy, immunotherapy, antigens, cell surface markers.

« Previous Next »
Graphical Abstract

[1]
Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: Implications for cancer therapy. Curr Protocols Pharmacol 2013; 14: 25.
[http://dx.doi.org/10.1002/0471141755.ph1425s61]
[2]
Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget 2017; 8(23): 38022-43.
[http://dx.doi.org/10.18632/oncotarget.16723] [PMID: 28410237]
[3]
Zhao L, Cao YJ, Engineered T, Engineered T. Engineered T cell therapy for cancer in the clinic. Front Immunol 2019; 10: 2250.
[http://dx.doi.org/10.3389/fimmu.2019.02250] [PMID: 31681259]
[4]
Sheykhhasan M, Manoochehri H, Naserpour L, Kalhor N. CAR-T cells: an innovative therapeutic strategy against pediatric acute lympho-blastic leukemia. Res Mol Med 2018; 6(2): 1-4.
[5]
Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257(1): 107-26.
[http://dx.doi.org/10.1111/imr.12131] [PMID: 24329793]
[6]
Lindner SE, Johnson SM, Brown CE, Wang LD. Chimeric antigen receptor signaling: Functional consequences and design implications. Sci Adv 2020; 6(21)eaaz3223
[http://dx.doi.org/10.1126/sciadv.aaz3223] [PMID: 32637585]
[7]
Akhoundi M, Mohammadi M, Sahraei SS, Sheykhhasan M, Fayazi N. CAR T cell therapy as a promising approach in cancer immunother-apy: Challenges and opportunities. Cell Oncol (Dordr) 2021; 44(3): 495-523.
[http://dx.doi.org/10.1007/s13402-021-00593-1] [PMID: 33759063]
[8]
Wang Q, Chen Y, Park J, et al. Design and production of bispecific antibodies. Antibodies (Basel) 2019; 8(3): 43.
[http://dx.doi.org/10.3390/antib8030043] [PMID: 31544849]
[9]
Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: Principles and clinical application. Clin Dev Immunol 2012; 2012980250
[http://dx.doi.org/10.1155/2012/980250] [PMID: 22474489]
[10]
Maryamchik E, Gallagher KME, Preffer FI, Kadauke S, Maus MV. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. Cytometry B Clin Cytom 2020; 98(4): 299-327.
[http://dx.doi.org/10.1002/cyto.b.21880]
[11]
Chang ZL, Chen YY. CARs: Synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med 2017; 23(5): 430-50.
[http://dx.doi.org/10.1016/j.molmed.2017.03.002] [PMID: 28416139]
[12]
Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: Functional and clinical considerations. Clin Transl Immunology 2019; 8(5)e1049
[http://dx.doi.org/10.1002/cti2.1049] [PMID: 31110702]
[13]
Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001; 103(2): 131-6.
[http://dx.doi.org/10.1046/j.1365-2567.2001.01235.x] [PMID: 11412299]
[14]
Liu B, Yan L, Zhou M. Target selection of CAR T cell therapy in accordance with the TME for solid tumors. Am J Cancer Res 2019; 9(2): 228-41.
[PMID: 30906625]
[15]
Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119(18): 4133-41.
[http://dx.doi.org/10.1182/blood-2011-12-400044] [PMID: 22354001]
[16]
Hoseini SS, Cheung NV. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Lett 2017; 399: 44-52.
[http://dx.doi.org/10.1016/j.canlet.2017.04.013] [PMID: 28428075]
[17]
Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther 2020; 5(1): 8.
[http://dx.doi.org/10.1038/s41392-020-0110-5] [PMID: 32296030]
[18]
Masoumi J, Jafarzadeh A, Abdolalizadeh J, et al. Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects. Acta Pharm Sin B 2021; 11(7): 1721-39.
[http://dx.doi.org/10.1016/j.apsb.2020.12.015] [PMID: 34386318]
[19]
Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med 2018; 7(1): 18.
[http://dx.doi.org/10.1186/s40169-018-0198-1] [PMID: 29984391]
[20]
Hu B, Zou Y, Zhang L, et al. Nucleofection with plasmid DNA for CRISPR/cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Hum Gene Ther 2019; 30(4): 446-58.
[http://dx.doi.org/10.1089/hum.2017.234] [PMID: 29706119]
[21]
Zhu X, Prasad S, Gaedicke S, Hettich M, Firat E, Niedermann G. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget 2015; 6(1): 171-84.
[http://dx.doi.org/10.18632/oncotarget.2767] [PMID: 25426558]
[22]
Klapdor R, Wang S, Hacker U, et al. Improved killing of ovarian cancer stem cells by combining a novel chimeric antigen receptor-based immunotherapy and chemotherapy. Hum Gene Ther 2017; 28(10): 886-96.
[http://dx.doi.org/10.1089/hum.2017.168] [PMID: 28836469]
[23]
Sauzay C, Voutetakis K, Chatziioannou A, Chevet E, Avril T. CD90/Thy-1, a cancer-associated cell surface signaling molecule. Front Cell Dev Biol 2019; 7: 66.
[http://dx.doi.org/10.3389/fcell.2019.00066] [PMID: 31080802]
[24]
Tan RPA, Leshchyns’ka I, Sytnyk V. Glycosylphosphatidylinositol-anchored immunoglobulin superfamily cell adhesion molecules and their role in neuronal development and synapse regulation. Front Mol Neurosci 2017; 10: 378.
[http://dx.doi.org/10.3389/fnmol.2017.00378] [PMID: 29249937]
[25]
Zhao W, Li Y, Zhang X. Stemness-related markers in cancer. Cancer Transl Med 2017; 3(3): 87-95.
[http://dx.doi.org/10.4103/ctm.ctm_69_16] [PMID: 29276782]
[26]
Lu B, Huang X, Mo J, Zhao W. Drug delivery using nanoparticles for cancer stem-like cell targeting. Front Pharmacol 2016; 7: 84.
[http://dx.doi.org/10.3389/fphar.2016.00084] [PMID: 27148051]
[27]
Alhabbab RY. Targeting cancer stem cells by genetically engineered chimeric antigen receptor T Cells. Front Genet 2020; 11: 312.
[http://dx.doi.org/10.3389/fgene.2020.00312] [PMID: 32391048]
[28]
Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am J Pathol 2007; 171(2): 386-95.
[http://dx.doi.org/10.2353/ajpath.2007.070152] [PMID: 17600130]
[29]
Imrich S, Hachmeister M, Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adhes Migr 2012; 6(1): 30-8.
[http://dx.doi.org/10.4161/cam.18953] [PMID: 22647938]
[30]
Macdonald J, Henri J, Roy K, et al. EpCAM immunotherapy versus specific targeted delivery of drugs. Cancers (Basel) 2018; 10(1): 19.
[http://dx.doi.org/10.3390/cancers10010019] [PMID: 29329202]
[31]
Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol 2015; 16(1): 1.
[http://dx.doi.org/10.1186/s12865-014-0064-x] [PMID: 25636521]
[32]
Guo Y, Feng K, Wang Y, Han W. Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment. Protein Cell 2018; 9(6): 516-26.
[http://dx.doi.org/10.1007/s13238-017-0394-6] [PMID: 28290053]
[33]
Xu H, Tian Y, Yuan X, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. OncoTargets Ther 2015; 8: 3783-92.
[http://dx.doi.org/10.2147/OTT.S95470] [PMID: 26719706]
[34]
Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: Therapeutic implications. J Hematol Oncol 2018; 11(1): 64.
[http://dx.doi.org/10.1186/s13045-018-0605-5] [PMID: 29747682]
[35]
Guo F, Cui J. CAR-T in cancer treatment: develop in self-optimization, win-win in cooperation. Cancers (Basel) 2021; 13(8): 1955.
[http://dx.doi.org/10.3390/cancers13081955] [PMID: 33921581]
[36]
Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: Challenges and opportunities. Stem Cell Res Ther 2021; 12(1): 81.
[http://dx.doi.org/10.1186/s13287-020-02128-1] [PMID: 33494834]

Rights & Permissions Print Cite
Article Metrics
17
© 2024 Bentham Science Publishers | Privacy Policy